布地奈德混悬液雾化吸入在儿童急性喉炎、喉气管支气管炎中的疗效观察

目的观察布地奈德？昆悬液治疗儿童急性喉炎、喉气管支气管炎的疗效。方法94例急性喉炎、喉气管支气管炎患儿随机分为观察组51例，治疗组43例。在常规治疗的基础上，观察组予布地奈德混悬液氧气驱动雾化吸入，对照组给予地塞米松氧气驱动雾化吸入，对两组治疗后症状、体征持续时间进行比较。结果治疗2h后观察组的症状评分为（1．55±0．64），显著低于对照组（1．84±0．57，P〈0．OS），但72h后治疗组的好转率以及治愈率分别为13．7％和86．3％，与对照组均无显著差异（14％和86％，均P〈0．05）。结论布地奈德混悬液氧气驱动雾化吸入治疗小儿急性喉炎起效快，能有效缓解喉部炎症，解除喉梗阻，避免全身使用激素的不良反应。

Efficacy of ebulized budesonide inhalation in treatment of acute laryngitis or acute laryngotracheobronchitis in children

Objective To observe the efficacy of nebulized budesonide （BUD） inhalation in the treatment of acute laryngitis or acute laryngotracheobronchitis in pediatric patients. Methods Ninety-four children with acute laryngitis or acute laryngotracheobronchitis, aged 6 months-5 years, were randomly divided into 2 groups： 51 undergoing inhalation of BUD suspension, 0.5 mg/time b.i.d, for 3-5d （observation group）, and 43 treated with inhalation of dexamethasome （DXM） 0.3N0. 5 m g/kg/d for 3 days in addition to conventional antibiotic or antiviral therapy , .The improvement of clinical manifestations were observed until 72 hours after the beginning of treatment. Results The score of clinical presentations 2 h after the beginning of treatment of the observation group was （1.55 ±0.64）, significantly lower than that of the control group （1.84±0.57, P 〈0.05）. However, there were no significant differences in the improvement rate and cure rate 72 hours after the beginning of treatment between these 2 groups （13.7% vs 14% and 86.3% vs 86% respectively, both P 〉0.05）.Conclusion For the children with acute laryngitis or acute laryngotracheobronchitis in addition to the routine anti-infection treatment inhalation of nenulized BUD is better than inhalation of DXM on improving the clinical manifestations and shortening the course of disease.